eli lilly and company zepbound - Search News

Order byBest matchMost fresh

News

Wegovy, Zepbound and Eli Lilly

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

Continue reading

· 1d · on MSN

Stocktwits on MSN · 1d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

BioSpace · 23h

Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy

9h

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

11d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

24/7 Wall St.1d

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

13don MSN

Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Results that may be inaccessible to you are currently showing.

Hide inaccessible results